Actuate Therapeutics

OverviewSuggest Edit

Actuate Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic agents for patients with cancer or inflammatory diseases. It has developed 9-ING-41 agent, which shows significant anti-tumor activity in many models of difficult-to-treat cancers, including cancers of the brain, pancreas, lung, breast, and lymphomas.

TypePrivate
Founded2015
HQFort Worth, TX, US
Websiteactuatetherapeutics.com

Latest Updates

Employees (est.) (Nov 2021)6
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Actuate Therapeutics

Daniel M. Schmitt

Daniel M. Schmitt

President & CEO, Director
Francis J. Giles

Francis J. Giles

Chief Medical Officer
Andrew P. Mazar

Andrew P. Mazar

Scientific Co-Founder
Richard Kenley

Richard Kenley

Vice President, Chemistry, Manufacturing, & Controls
Aaron G.l. Fletcher

Aaron G.l. Fletcher

Chairman
Les Kreis

Les Kreis

Director
Show more

Actuate Therapeutics Office Locations

Actuate Therapeutics has offices in Fort Worth and Dublin
Fort Worth, TX, US (HQ)
1751 River Run #400
Show all (2)

Actuate Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2015

Actuate Therapeutics total Funding

$31.2 m

Actuate Therapeutics latest funding size

$6.5 m

Time since last funding

2 years ago

Actuate Therapeutics investors

Actuate Therapeutics's latest funding round in November 2019 was reported to be $6.5 m. In total, Actuate Therapeutics has raised $31.2 m
Show all financial metrics

Actuate Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Actuate Therapeutics Online and Social Media Presence

Embed Graph

Actuate Therapeutics News and Updates

Actuate Therapeutics Announces Initiation Of Phase 2 Clinical Study In Pancreatic Cancer

Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced enrollment of the first patients with first-line advanced pancreatic cancer in a phase 2 study of 9-ING-41, as a new arm of the ongoing phase 1/2 1801 trial of 9-ING-41, (NCT03678883, EudraCT#:2018-0037…

Actuate Therapeutics Frequently Asked Questions

  • When was Actuate Therapeutics founded?

    Actuate Therapeutics was founded in 2015.

  • Who are Actuate Therapeutics key executives?

    Actuate Therapeutics's key executives are Daniel M. Schmitt, Francis J. Giles and Andrew P. Mazar.

  • How many employees does Actuate Therapeutics have?

    Actuate Therapeutics has 6 employees.

  • Who are Actuate Therapeutics competitors?

    Competitors of Actuate Therapeutics include GlycoMimetics, Corvus Pharmaceuticals and Immunovative Therapies.

  • Where is Actuate Therapeutics headquarters?

    Actuate Therapeutics headquarters is located at 1751 River Run #400, Fort Worth.

  • Where are Actuate Therapeutics offices?

    Actuate Therapeutics has offices in Fort Worth and Dublin.

  • How many offices does Actuate Therapeutics have?

    Actuate Therapeutics has 2 offices.